vs
康代（CAMT）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
康代的季度营收约是Esperion Therapeutics, Inc.的1.4倍（$242.0M vs $168.4M）
康代有限公司是全球领先的高精度检测与计量系统研发生产商，服务半导体、印刷电路板、先进封装等领域，为亚洲、北美、欧洲的客户提供工艺控制、缺陷检测、良率优化等相关解决方案。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
CAMT vs ESPR — 直观对比
营收规模更大
CAMT
是对方的1.4倍
$168.4M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $242.0M | $168.4M |
| 净利润 | $68.0M | — |
| 毛利率 | 50.9% | — |
| 营业利润率 | 26.7% | 50.6% |
| 净利率 | 28.1% | — |
| 营收同比 | — | 143.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAMTESPR
| Q4 25 | — | $168.4M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | $242.0M | $82.4M | ||
| Q1 25 | — | $65.0M | ||
| Q4 24 | — | $69.1M | ||
| Q3 24 | — | $51.6M | ||
| Q2 24 | $199.6M | $73.8M | ||
| Q1 24 | — | $137.7M |
净利润CAMTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | $-31.3M | ||
| Q2 25 | $68.0M | $-12.7M | ||
| Q1 25 | — | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-29.5M | ||
| Q2 24 | $52.8M | $-61.9M | ||
| Q1 24 | — | $61.0M |
毛利率CAMTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 50.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | — | — |
营业利润率CAMTESPR
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | -11.4% | ||
| Q2 25 | 26.7% | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | — | -31.0% | ||
| Q2 24 | 23.6% | 3.5% | ||
| Q1 24 | — | 52.5% |
净利率CAMTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | -35.9% | ||
| Q2 25 | 28.1% | -15.4% | ||
| Q1 25 | — | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -57.2% | ||
| Q2 24 | 26.4% | -83.9% | ||
| Q1 24 | — | 44.3% |
每股收益（稀释后）CAMTESPR
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $232.0M | $167.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $626.5M | $-302.0M |
| 总资产 | $974.7M | $465.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CAMTESPR
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | $232.0M | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | $109.8M | $189.3M | ||
| Q1 24 | — | $226.6M |
股东权益CAMTESPR
| Q4 25 | — | $-302.0M | ||
| Q3 25 | — | $-451.4M | ||
| Q2 25 | $626.5M | $-433.5M | ||
| Q1 25 | — | $-426.2M | ||
| Q4 24 | — | $-388.7M | ||
| Q3 24 | — | $-370.2M | ||
| Q2 24 | $475.4M | $-344.2M | ||
| Q1 24 | — | $-294.3M |
总资产CAMTESPR
| Q4 25 | — | $465.9M | ||
| Q3 25 | — | $364.0M | ||
| Q2 25 | $974.7M | $347.1M | ||
| Q1 25 | — | $324.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | — | $314.1M | ||
| Q2 24 | $796.2M | $352.3M | ||
| Q1 24 | — | $373.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $47.1M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 0.69× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CAMTESPR
| Q4 25 | — | $45.2M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | $47.1M | $-31.4M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-35.0M | ||
| Q3 24 | — | $-35.3M | ||
| Q2 24 | $70.1M | $-7.2M | ||
| Q1 24 | — | $53.8M |
自由现金流CAMTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
自由现金流率CAMTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
资本支出强度CAMTESPR
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
现金转化率CAMTESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.33× | — | ||
| Q1 24 | — | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAMT
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
